Neil Shah

Fame in the music business can be fleeting. John Janick’s goal is to turn singers like Olivia Rodrigo and Billie Eilish into ‘generational’ talents.

From ‘The Boss’ to Madonna, high-profile artists are rescheduling tours, creating headaches for venues

In Svenhard’s Swedish Bakery v. United States Bakery, Bk. No. 19-15277, 2023 WL 5541420 (9th Cir. Aug. 29, 2023), the Ninth Circuit held that a…

The clock was ticking closer to the deadline for filing the Annual Return (GSTR 9) and Reconciliation Statement (GSTR 9C) for the financial year that concluded on March 31, 2023. We could see a wave of apprehension ripple through the landscape of indirect tax compliance. It was not just about meeting the requirements but navigating the intricate web of compliance that demanded attention in the subsequent three months. The burning question looms: Can businesses successfully manoeuvre through this maze and ensure complete compliance before the looming deadline of December 31, 2023? Let's delve deeper into the complexities and challenges that businesses and taxpayers face in the realm of Goods and Services Tax (GST).

"​The growing consumption of streaming multimedia, gaming, and social media (not only download but upload) as well will accelerate the need for the 5G smartphone upgrades.

In the realm of finance and investing, the path to success is often paved with unique experiences and unexpected opportunities.

The recently enacted Digital Personal Data Protection Act, 2023 (“DPA”) introduces a notable exemption in its applicability, exempting personal data of an individual that is made publicly available by the same individual. DPA itself provides a scenario as an illustration of this principle: an individual, X, while blogging her views, has publicly made available her personal data on social media. Consequently, the personal data of X published by her on social media would not fall within protective ambit of the DPA. This exclusion, we argue, significantly dilutes the primary objective of the DPA of safeguarding the right of individuals to protect their personal data.

India's online gaming industry, often referred to as iGaming, has experienced a whirlwind in 2023. The imposition of a 28% Goods and Services Tax (GST) on all iGaming companies, coupled with a lack of clear regulatory guidelines, created a maelstrom of confusion and uncertainty. To chart a course towards robust growth for this burgeoning sector, a critical distinction needs to be established: the fundamental difference between games of skill and games of chance.

Neil Shah has been a non-profit CFO at various organizations for almost 20 years. He is currently the CFO at Achievement First

Purpose: Immune-related cutaneous adverse events (ircAEs) occur in ≥50% of patients treated with checkpoint inhibitors (CPI), but mechanisms are poorly understood. Experimental Design: Phenotyping/biomarker analyses were conducted in 200 patients on CPIs (139 with ircAEs, 61 without, control) to characterize their clinical presentation and immunologic endotypes. Cytokines were evaluated in skin biopsies, skin tape strip (STS) extracts and plasma using real-time PCR and Meso Scale Discovery multiplex cytokine assays. Results: Eight ircAE phenotypes were identified: pruritus (26%), maculopapular rash (MPR; 21%), eczema (19%), lichenoid (11%), urticaria (8%), psoriasiform (6%), vitiligo (5%), and bullous dermatitis (4%). All phenotypes showed skin lymphocyte and eosinophil infiltrates. Skin biopsy PCR revealed the highest increase in IFN-gamma mRNA in patients with lichenoid (p<0.0001) and psoriasiform dermatitis (p<0.01) as compared to patients without ircAEs, while the highest IL-13 mRNA levels were detected in the eczema (p<0.0001, compared to control). IL-17A mRNA was selectively increased in psoriasiform (p<0.001), lichenoid (p<0.0001), bullous dermatitis (p<0.05) and MPR (p<0.001), compared to control. Distinct cytokine profiles were confirmed in STS and plasma. Analysis determined increased skin/plasma IL-4 cytokine in pruritus, skin IL-13 in eczema, plasma IL-5 and IL-31 in eczema and urticaria, and mixed-cytokine pathways in MPR. Broad inhibition via corticosteroids or type 2-cytokine targeted inhibition resulted in clinical benefit in these ircAEs. In contrast, significant skin upregulation of type 1/type 17 pathways was found in psoriasiform, lichenoid, bullous dermatitis, and type 1 activation in vitiligo. Conclusions: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.